Investigational drug · Phase 3
BCG
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
435
Any phase or sponsor naming "BCG"
First trial start
2014
Jul 21, 2014
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BCG", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Papillary-Only Non-muscle-invasive Bladder Cancer
- Tuberculosis
- Bladder Cancer
- NMIBC
- Non-muscle Invasive Bladder Cancer
- Non-Muscle- Invasive Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Tuberculosis · Oncology · Infectious disease and vaccines · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "BCG" as an intervention, largest first.
- Non-specific Effects of BCG in Under-five ChildrenStatus unknown
Universidade Nova de LisboaAcademic, hospital or other
NCT05471167 · 80,000 participants (planned) · Start Jan 1, 2022 · Primary completion Dec 31, 2022
Drug: BCG · For: Immunity, Heterologous
Sites: Lisbon, Portugal
- Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?Pivotal-lookingActive, not recruiting
Bandim Health ProjectAcademic, hospital or other
NCT04658680 · 22,800 participants (planned) · Start Feb 25, 2021 · Primary completion Mar 2026
Drug: BCG vaccination at first health facility contact · For: Infant Mortality; BCG
Sites: Bissau, Guinea-Bissau
- Comparing Morbidity and Mortality Effects of Two Different Strains of BCGPivotal-lookingCompleted
Bandim Health ProjectAcademic, hospital or other
NCT03400878 · 17,505 participants · Start Oct 14, 2017 · Primary completion Jun 1, 2020
Drug: BCG-Japan; BCG-Russia · For: Heterologous Immunity; Infant Morbidity; Infant Mortality and 3 more
Sites: Bissau, Guinea-Bissau · 2 sites in all
- Trial to Compare Two Strains of BCGPivotal-lookingCompleted
Bandim Health ProjectAcademic, hospital or other
NCT04383925 · 16,390 participants · Start May 4, 2020 · Primary completion Oct 30, 2022
Drug: BCG-Japan; BCG-Russia · For: Death, Infant; Morbidity;Infant
Sites: Bissau, Guinea-Bissau
- Trial to Compare BCG-Bulgaria and BCG-DenmarkPivotal-lookingStatus unknown
Bandim Health ProjectAcademic, hospital or other
NCT05397678 · 15,000 participants (planned) · Start Oct 21, 2022 · Primary completion Jul 2024
Drug: BCG-Denmark; BCG-Bulgaria · For: Death; Neonatal; Death, Infant; Morbidity;Newborn and 2 more
Sites: Bissau, Guinea-Bissau
- Trial of Two Strains of BCGPivotal-lookingCompleted
Bandim Health ProjectAcademic, hospital or other
NCT02447536 · 12,006 participants · Start Dec 8, 2014 · Primary completion Nov 24, 2017
Drug: BCG-Denmark 1331 (Statens Serum Institute); BCG-Russia-I (Serum Institute of India) · For: Morbidity; Bacille Calmette-Guérin
Sites: Bissau, Guinea-Bissau
- Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination.Pivotal-lookingStatus unknown
University of Cape TownAcademic, hospital or other
NCT00242047 · 12,000 participants · Start Mar 2001
Drug: Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG). · For: Tuberculosis
Sites: Cape Town, South Africa
- BCG Revaccination in Children and AdolescentsPivotal-lookingSuspended
Tuberculosis Research Centre, IndiaGovernment (non-federal)
NCT05330884 · 9,200 participants (planned) · Start Jul 15, 2024 · Primary completion Jun 2027
Drug: BCG vaccine; Oral Chemoprophylaxis · For: Tuberculosis Infection; Tuberculosis
Sites: Chennai, India
- Vitamin A Supplementation With Bacille Calmette Guerin (BCG) VaccinePivotal-lookingStatus unknown
Bandim Health ProjectAcademic, hospital or other
NCT00168610 · 7,600 participants · Start Nov 2004
Drug: Vitamin A · For: Infant Mortality; Morbidity
Sites: Bissau, Guinea-Bissau
- Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan AfricaPivotal-lookingRecruiting
Biofabri, S.LIndustry
NCT04975178 · 7,120 participants (planned) · Start Oct 17, 2022 · Primary completion Feb 2029
Drug: MTBVAC; BCG · For: Tuberculosis
Sites: Worcester, South Africa
Newest research
PubMed records naming it or its code names, newest first.
- Spurious undetectable albumin due to hemodialysis catheter lock contamination.
Naml A, Turgut HA, Şeneş M · Clin Chim Acta 2027
- Childhood vaccination timeliness, under-immunization-for-age and measles effective immunity in Peru: a province and birth-cohort analysis of national survey data, 2004-2025.
Rojas JD, Huarachi-Napa CR, Salazar-Buitron SZ, et al. · Vaccine 2027
- Analytical and clinical performance evaluation of the STANDARDࡊ M10 MTB/NTM assay for the simultaneous detection of Mycobacterium tuberculosis and nontuberculous mycobacteria.
Son ES, Lee SY, Lee MJ, et al. · Diagn Microbiol Infect Dis 2027
- Rising BCG toxicity in Brazil: is the substrain the whole story?
Korkes F, Morrone MC, Kamat AM · Int Braz J Urol 2027
- Changes in full vaccination coverage and in the gap between poor and non-poor households among children aged 12-23ߙmonths in the Democratic Republic of the Congo, 2013-14 to 2023-24: a comparison of two Demographic and Health surveys.
Tsala Dimbuene Z, Mabanza Matondo S, Muleka Ilunga B, et al. · Glob Health Action 2026
- IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.
Goldman CK · Oncoimmunology 2026
Also in development for Non-muscle Invasive Bladder Cancer (NMIBC)
- FL115Phase 22 trials
Suzhou Forlong Biotechnology Co., Ltd · Advanced Solid Tumors, Non-muscle Invasive Bladder Cancer (NMIBC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.